Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction

References

• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1993;340:115–126.
   Google Scholar
• Emsley J, White HE, O’Hara BP, et al. Structure of pentameric human serum amyloid P component. Nature. 1994;367(6461):338–345. doi:10.1038/367338a0
   PubMed Web of Science ®Google Scholar
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366. doi:10.1146/annurev.immunol.23.021704.115756
   PubMed Web of Science ®Google Scholar
• Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in cardiovascular disease. Front Immunol. 2019;10:823. doi:10.3389/fimmu.2019.00823
   PubMed Web of Science ®Google Scholar
• Ibanez B, Lames S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Introna M, Vidal Alles V, Castellano M, et al. Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–1872. doi:10.1182/blood.V87.5.1862.1862
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349. doi:10.1161/01.CIR.0000145167.30987.2E
   PubMed Web of Science ®Google Scholar
• Akgul O, Baycan OF, Nakano A, et al. Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26:592–597. doi:10.1097/MCA.0000000000000280
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. doi:10.1002/ejhf.592
   PubMed Web of Science ®Google Scholar
• Janssens GN, van der Hoeven NW, Lemkes JS, et al. 1-year outcomes of delayed versus immediate intervention in patients with transient ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2019;12(22):2272–2282. doi:10.1016/j.jcin.2019.07.018
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi:10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol. 2011;58(1):38–45. doi:10.1016/j.jjcc.2011.03.006
   PubMedGoogle Scholar
• Kimura S, Sugiyama T, Hishikari K, et al. Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris. Atherosclerosis. 2020;292:127–135. doi:10.1016/j.atherosclerosis.2019.11.022
   PubMed Web of Science ®Google Scholar
• Demir MT, Baydin A, Amanvermez R, Erenler AK, Güzel M, Yücel O. Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome. Bratisl Lek Listy. 2018;119(8):509–512. doi:10.4149/BLL_2018_093
   PubMedGoogle Scholar
• George M, Shanmugam E, Srivatsan V, et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study. Ther Adv Cardiovasc Dis. 2015;9(5):275–284. doi:10.1177/1753944715578405
   PubMedGoogle Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636. doi:10.1161/01.CIR.102.6.636
   PubMed Web of Science ®Google Scholar
• Fornai F, Carrizzo A, Forte M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016;13(1):25. doi:10.1186/s12979-016-0080-1
   PubMedGoogle Scholar
• Marie T, Jiri J, Josef T, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers. 2015;2015:1–11.
   Google Scholar
• Mjelva ØR, Pönitz V, Brügger-Andersen T, et al. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. Eur J Prev Cardiol. 2016;23(11):1130–1140. doi:10.1177/2047487315619733
   PubMed Web of Science ®Google Scholar
• Kontny F, Andersen T, Ueland T, et al. Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: a substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. Eur Heart J. 2019;9(4):313–322.
   Google Scholar
• Khamitova AF, Lakman IA, Akhmetvaleev RR, et al. Multifactor predictive model in patients with myocardial infarction based on modern biomarkers. Kardiologiia. 2020;60(3):14–20. doi:10.18087/cardio.2020.3.2593
   PubMedGoogle Scholar
• Altay S, Çakmak HA, Kemaloğlu ÖZT, et al. Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. Anatol J Cardiol. 2017;17(3):202–209. doi:10.14744/AnatolJCardiol.2016.7307
   PubMedGoogle Scholar
• Dharma S, Sari NY, Santoso A, et al. Association of plasma pentraxin 3 concentration with angiographic and clinical outcomes in patients with acute ST-segment elevation myocardial infarction treated by primary angioplasty. Catheter Cardiovasc Interv. 2020;96(6):1233–1239. doi:10.1002/ccd.28626
   PubMed Web of Science ®Google Scholar
• Ljuca F, Hadžiefendić B, Jahić E, et al. Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation. Saudi Med J. 2019;40(12):1202–1208. doi:10.15537/smj.2019.12.24737
   PubMed Web of Science ®Google Scholar
• Eggers KM, Armstrong PW, Califf RM, et al. Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. Clin Biochem. 2013;46(16–17):1655–1659. doi:10.1016/j.clinbiochem.2013.08.014
   PubMed Web of Science ®Google Scholar
• Luo X-Y, Zhu X-Q, Li Y, et al. MicroRNA-150 restores endothelial cell function and attenuates vascular remodeling by targeting PTX3 through the NF-κB signaling pathway in mice with acute coronary syndrome. Cell Biol Int. 2018;42(9):1170–1181. doi:10.1002/cbin.10985
   PubMedGoogle Scholar
• Balhara J, Shan L, Zhang J, et al. Pentraxin 3 deletion aggravates allergic inflammation through a T17-dominant phenotype and enhanced CD4 T-cell survival. J Allergy Clin Immunol. 2017;139(3):950–963.e9. doi:10.1016/j.jaci.2016.04.063
   PubMedGoogle Scholar
• Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163–179.
   PubMed Web of Science ®Google Scholar